【活動快訊】國際行家解密投資趨勢,布局獲利前景!

撰文新聞中心
日期2021-06-18
Vivo Capital、Polaris Partners、Jefferies投資銀行、Epidarex Capital、Onward Therapeutics、台康等產業資深經理人,深入討論生醫企業IPO與併購之布局前景。

國際投資機構齊聚亞洲生技大會

Vivo Capital、Polaris Partners、Jefferies、Epidarex Capital 

亞洲生技大會邀請Vivo Capital合夥人Honbo Lu、Polaris Partners合夥人Darren Carroll、Jefferies投資銀行總經理Michael Brinkman、Epidarex Capital執行長Sinclair Dunlop、Sanofi Pasteur BD&L Global Head Donna Martin與亞太總監Matthieu Merlin以及Onward Therapeutics葉常菁董事長、台康生技劉理成總經理深入討論生醫企業IPO與併購之布局前景。

>> 立即報名

>> 議程資訊

 
BIO Asia-Taiwan 2021 Online + Onsite

Asian region persists in developing quality research, cutting-edge technology, and innovative businesses. Moreover, there are diverse exit strategies available, and many developing biotech companies have received favorable valuations in capital and public markets.

 

Join us at BIO Asia-Taiwan 2021 to explore solid growth and exit strategies for biotech in Asia, with an expert panel discussion on identifying value and building strategic partnerships. Explore our company presentations and entrepreneur pitches, as well as the engagement opportunities with state-of-the-art partnering system!

 
REGISTER NOW
Learn More

Joseph Chou

Chairman and CEO,
PwC Taiwan

Hongbo Lu

Partner,
Vivo Capital

Michael Brinkman

Managing Director,
Joint US Head of Biopharmaceuticals Investment Banking, Jefferies, LLC

Darren Carroll

Partner, Polaris Partners, previously Chief Business Officer, Eli Lilly

Sinclair Dunlop

Managing Director,
Epidarex Capital

Grace Yeh

Chairman & CEO,
Onward Therapeutics

Lee-Cheng Liu

President & CEO,
Eirgenix

REGISTER NOW!
 

Sponsor by